Suppr超能文献

用于HIV-1核酸检测标准化的HIV-1亚型RNA检测板的开发与评估

Development and evaluation of HIV-1 subtype RNA panels for the standardization of HIV-1 NAT assays.

作者信息

Lee Sherwin, Wood Owen, Taffs Rolf E, Hu Jinjie, Machuca Ana, Vallejo Alejandro, Hewlett Indira

机构信息

Laboratory of Molecular Virology, Division of Emerging and Transfusion Transmitted Diseases, Center for Biologics Evaluation and Research, US FDA, 1401 Rockville Pike (HFM-315), Rockville, MD 20852, United States.

出版信息

J Virol Methods. 2006 Nov;137(2):287-91. doi: 10.1016/j.jviromet.2006.07.001. Epub 2006 Aug 22.

Abstract

Multiple nucleic acid-based techniques (NAT) have been implemented for testing blood and plasma donors for HIV-1 RNA which may be detected at an earlier stage of infection when HIV antigen or antibody is absent or below the limit of detection of current assays. The available NAT assays are based on different technologies. In order to evaluate the performance of nucleic acid-based techniques (NAT assays) and to allow accurate comparisons of results from different assays, it is essential to have well characterized specimens with known copy numbers as a standard. For this purpose, a comprehensive study was conducted to develop two HIV-1 RNA reference panels. The first (Panel 1) was prepared using a single specimen from the HIV-1 group M subtype B and consists of panel members with a wide range of HIV-1 RNA copy numbers. Panel 2 consists of 26 members representing HIV-1 group M subtypes A, C, D, E, F, G and groups O and N. For accurate determination of HIV-1 RNA copy numbers of each member of Panel 2, they were analyzed using various testing platforms/technologies available through the cooperation of five independent laboratories participating in the study. A consensus value for HIV RNA copy number was assigned to each member of Panel 2 based on statistical analysis of the data provided by the participants. Both panels could serve as reference panels to be used by manufacturers of HIV NAT tests to evaluate the sensitivity limits of their assays.

摘要

已采用多种基于核酸的技术(NAT)对血液和血浆捐献者进行HIV-1 RNA检测,在感染早期,当HIV抗原或抗体缺失或低于当前检测方法的检测限时,仍可检测到HIV-1 RNA。现有的NAT检测方法基于不同技术。为了评估基于核酸的技术(NAT检测)的性能,并能准确比较不同检测方法的结果,拥有已知拷贝数且特征明确的标本作为标准至关重要。为此,开展了一项全面研究以开发两个HIV-1 RNA参考品组。第一个(品组1)使用来自HIV-1 M组B亚型的单个标本制备,由具有广泛HIV-1 RNA拷贝数的品组成员构成。品组2由26个成员组成,代表HIV-1 M组的A、C、D、E、F、G亚型以及O组和N组。为准确测定品组2每个成员的HIV-1 RNA拷贝数,通过参与该研究的五个独立实验室合作,使用各种可用的检测平台/技术对其进行了分析。基于参与者提供的数据的统计分析,为品组2的每个成员指定了HIV RNA拷贝数的一致值。这两个品组均可作为HIV NAT检测制造商用于评估其检测方法灵敏度极限的参考品组。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验